Search

Gdf -11 a new target to improve anemia in thalassemia.

 

β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.

Read more

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.

Read more

Connecting experts on inherited anemias and iron defects in Budapest

October 12-14, 2023 – Budapest, Hungary 

Meeting Chairs: 
Ali Taher, American University of Beirut Medical Center, Beirut, Lebanon 

Achille Iolascon, University Federico II of Naples, Naples, Italy 

In October 2023 EHA and the Specialized Working Group (SWG) on Red Cell and Iron hosted a…

Read more

I4MDS consortium: advancing MDS treatment and understanding

The role of the immune system in the pathophysiology of Myelodysplastic Neoplasms (MDS) is firmly established. However, routine immune monitoring for these patients is still not a common practice.

Read more

Expert opinions for COVID-19 vaccination in patients with hematologic cancer

Ronja Brockhoff, Hamdi Akan, Rafael Duarte, Martin Hönigl, Nikolay Klimko, Sibylle C. Mellinghoff, Livio Pagano, Antonio Pagliuca, Paul Verweij, Oliver A.

Read more

EHA-PTHiT Hematology Tutorial on Novel Treatment Approaches in Hematologic Malignancies

EHA in collaboration with the Polish Society for Hematology and Transfusion (PTHiT) have decided to postpone this highly anticipated Hematology Tutorial to a future date, to be announced.

Read more